Sensex sinks 300 pts, Midcap plunges 2%
Panacea Biotec has received establishment inspection report from the US Food and Drug Administration indicating the formal closure of the current good manufacturing practise and pre-approval inspection conducted by USFDA, at its oncology parenteral and oral solids dosage formulation facilities at Malpur, Baddi, District Solan, Himachal Pradesh.
The oral solids manufacturing facility located at Baddi site has a history of completion of four consecutive successful current good manufacturing practise and pre-approval inspections by USFDA in last 7 years. The manufacturing facility of oncology parenteral formulations has been inspected successfully for the first time by USFDA.
Panacea Biotec has received establishment inspection report from the US Food and Drug Administration indicating the formal closure of the current good manufacturing practise and pre-approval inspection conducted by USFDA, at its oncology parenteral and oral solids dosage formulation facilities at Malpur, Baddi, District Solan, Himachal Pradesh. 
No comments:
Post a Comment